151 related articles for article (PubMed ID: 25188474)
1. Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene.
Savas P; Caramia F; Teo ZL; Loi S
Curr Opin Oncol; 2014 Nov; 26(6):562-7. PubMed ID: 25188474
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Savas P; Salgado R; Denkert C; Sotiriou C; Darcy PK; Smyth MJ; Loi S
Nat Rev Clin Oncol; 2016 Apr; 13(4):228-41. PubMed ID: 26667975
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
Luen SJ; Savas P; Fox SB; Salgado R; Loi S
Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
[TBL] [Abstract][Full Text] [Related]
5. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
[TBL] [Abstract][Full Text] [Related]
6. The role of the HER-2/neu oncogene in gynecologic cancers.
Cirisano FD; Karlan BY
J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
[TBL] [Abstract][Full Text] [Related]
7. Tumor infiltrating lymphocytes in early breast cancer.
Pruneri G; Vingiani A; Denkert C
Breast; 2018 Feb; 37():207-214. PubMed ID: 28363679
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of tumor-infiltrating lymphocytes in breast cancer: How to use the 2014 international guidelines?].
Joyon N; Kordahi M; Blanc-Fournier C; Lacroix-Triki M
Ann Pathol; 2017 Feb; 37(1):127-132. PubMed ID: 28159402
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.
Chen WC; Lai YH; Chen HY; Guo HR; Su IJ; Chen HH
Histopathology; 2013 Aug; 63(2):225-33. PubMed ID: 23738752
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.
Melichar B; Študentova H; Kalábová H; Vitásková D; Čermáková P; Hornychová H; Ryška A
Anticancer Res; 2014 Mar; 34(3):1115-25. PubMed ID: 24596349
[TBL] [Abstract][Full Text] [Related]
11. The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes.
Duechler M; Peczek L; Zuk K; Zalesna I; Jeziorski A; Czyz M
Immunobiology; 2014 Feb; 219(2):158-65. PubMed ID: 24091277
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
13. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast.
Lim KH; Telisinghe PU; Abdullah MS; Ramasamy R
Cancer Immun; 2010 Jan; 10():3. PubMed ID: 20092246
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers.
Tsang JY; Hui SW; Ni YB; Chan SK; Yamaguchi R; Kwong A; Law BK; Tse GM
Breast Cancer Res Treat; 2014 Jan; 143(1):1-9. PubMed ID: 24272079
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.
Ravelli A; Roviello G; Cretella D; Cavazzoni A; Biondi A; Cappelletti MR; Zanotti L; Ferrero G; Ungari M; Zanconati F; Bottini A; Alfieri R; Petronini PG; Generali D
Tumour Biol; 2017 Apr; 39(4):1010428317695023. PubMed ID: 28378631
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Lee AH; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 May; 127(1):99-108. PubMed ID: 20556505
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
20. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
